Ph.D.Visiting Professor Tomoyuki Mizuno
Pharmacometrics is a novel discipline that quantitatively analyzes and predicts drug responses (pharmacokinetics, efficacy, and toxicity) using mathematical models and simulation technologies. Systems Pharmacology views the human body and diseases as systems, quantitatively elucidating drug-patient-disease interactions by combining mathematical models with experimental data. Our research group utilizes pharmacometrics and systems pharmacology, both emerging data sciences, to predict disease progression, drug effects, and the incidence of adverse drug reactions at both population and individual levels, informing optimal therapeutic strategies in both clinical medication use and drug development.
Research and Education
Our research aims to advance rational medication use through the integration of pharmacometrics and systems pharmacology modeling. We engage in collaborative efforts to develop precision dosing strategies, enhancing personalized therapeutic optimization at the bedside and supporting efficient, safe drug development.
We closely collaborate with the Department of Pharmacy at Kyoto University Hospital to develop personalized dosing strategies for various therapeutic areas, particularly where precise dosing control is crucial for optimal outcomes. Leveraging mathematical models and AI/machine learning, we implement model-informed precision dosing (MIPD) strategies to address unmet clinical needs. Additionally, as part of the newly established Pharmacometrics team (PMx Team) within the Institute for Advanced Clinical and Translational Science (iACT), we contribute to rational drug development using quantitative model-based approaches (model-informed drug development: MIDD).
Our research and education efforts involve close collaboration with our research lab at Cincinnati Children’s Hospital Medical Center, fostering international collaboration and providing high-level education for the next generation of global scientists in clinical pharmacology, pharmacometrics, and systems pharmacology.
Figure 1: Concept of Model-informed precision dosing (MIPD). Adapted from Mizuno T et al. Br J Clin Pharmacol 2022 Feb;88(4):1418-1426.
Figure 2: Application of AI/ML approaches on personalized precision dosing. Adapted from Poweleit EA, Vinks AA, Mizuno T. Ther Drug Monit. 2023 Apr 1;45(2):143-150.
Recent Publications
- Yamashita Y, Hira D, Morita M, Katsube Y, Takakura M, Tomotaki H, Tomotaki S, Xiong W, Shiomi H, Horie T, Ueshima S, Mizuno T, Terada T, Ono K. Potential Treatment Option of Rivaroxaban for Breastfeeding Women: A Case Series. Thromb Res. 2024 May;237:141-144.
- van Hoogdalem M, Tanaka R, Abduljalil K, Johnson TN, Wexelblatt SL, Akinbi HT, Vinks AA, Mizuno T. Forecasting fetal buprenorphine exposure through maternal-fetal physiologically-based pharmacokinetic modeling. Pharmaceutics. 2024 Mar 8;16(3):375.
- Poweleit EA, Vinks AA, Mizuno T. Artificial Intelligence and Machine Learning Approaches to Facilitate Therapeutic Drug Management and Model-Informed Precision Dosing. Ther Drug Monit. 2023 Apr 1;45(2):143-150.
- van Hoogdalem, M, Johnson TN, McPhail BT, Kamatkar S, Wexelblatt SL, Ward LP, Christians U, Akinbi HT, Vinks AA, Mizuno T. Physiologically-based pharmacokinetic modeling to investigate the effect of maturation on buprenorphine pharmacokinetics in newborns with neonatal opioid withdrawal syndrome. Clin Pharmacol Ther. 2022 Feb;111(2):496-508.
- Xiong Y, Mizuno T, Colman R, Hyams J, Noe JD, Boyle B, Tsai YT, Dong M, Jackson K, Punt N, Rosen MJ, Denson LA, Vinks AA, Minar P. Real-world Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn’s. Clin Pharmacol Ther. 2021 Jun;109(6):1639-1647.
Laboratory
[Visiting Professor] Tomoyuki Mizuno, PhD
e-mail: mizunot@kuhp.kyoto-u.ac.jp
e-mail: tomoyuki.mizuno@cchmc.org (CCHMC)